Selected Publications

Coleman KD, McKinley K, Ellison AM, Alpern ER, Hariharan S, Topoz I, Wurtz M, Nielsen B, Cook LJ, Morris CR, Brandow AM, Campbell AD, Liem RI, Nuss R, Quinn CT, Thompson AA, Villella A, King AA, Baumann A, Frankenberger W, Brousseau DC; PECARN Registry Working Group: Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease. Pediatric Blood Cancer e31750, July 2025 Notes: DOI: 10.1002/pbc.31750.

Prussien KV, Burke MM, Gollomp K, Wright RJ, Thompson AA.: Cortisol in Sickle Cell Disease: A Systematic Review and Meta-Analysis. Blood Advance June 2025 Notes: DOI: 10.1182/bloodadvances.2024015425.

Gibson NM, Khandros E, Elgarten CW, Worster E, Monos DS, Thompson AA, Kwiatkowski JL, Olson T. : Impact of HLA Alloimmunization in Gene Modified. Blood Page: 2666-2670, May 2025 Notes: doi: 10.1182/blood.2024027034.

Hildenbrand AK, Mara CA, Murphy B, Hood AM, Johnson Y, Shook LM, Real FJ, Nwankwo C, Hackworth R, Badawy SM, Thompson AA, Raphael JL, Smith-Whitley K, King AA, Calhoun C, Creary SE, Reader SK, Bhasin N, Sobota AE, Houston P, Gipson C, DeBaun MR, Saving KL, Treadwell M, Quinn CT, Crosby LE. : Engaging Parents of Children with Sickle Cell Disease in Shared Decision Making for Hydroxyurea: The ENGAGE-HU Study Pediatr Blood Cancer Page: e31639, March 2025 Notes: 2025 Mar 6: e31639. doi: 10.1002 /pbc.31639. Online ahead of print.

Rollins MR, Warsame RM, Smith M, Molina A, Rouce RH, Avalos BR, Johnson CS, Lopez JA, Thompson AA, Fanning L, Frustace P, Roche K, van Havre N, Mack D, Flowers CR, Terrell DR. : American Society of Hematology: building a comprehensive minority recruitment and retention professional program. Blood Advance Page: 6237-6247, December 2024 Notes: doi: 10.1182/bloodadvances.2024013519.

Kwiatkowski JL, Walters MC, Hongeng S, Yannaki E, Kulozik AE, Kunz JB, Sauer MG, Thrasher AJ, Thuret I, Lal A, Tao G, Ali S, Thakar HL, Elliot H, Lodaya A, Lee J, Colvin RA, Locatelli F, Thompson AA: Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet Page: 2175-2186, November 2024 Notes: 2024 Nov 30;404(10468) doi: 10.1016/S0140-6736(24)01884-1.

Shook LM, Rosen BL, Mara CA, Mosley C, Thompson AA, Smith-Whitley K, Schwartz L, Barriteau C, King A, Oke E, Jallow F, Murphy B, Crosby L.: Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease. J Pediatr Hematol Onco July 2024.

Kwiatkowski JL, Thompson AA, Tricta F, Temin NT, Rozova A, Fradette C, Badawy SM.: Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years. Am J Hematol. 2024 March 2024.

Gordon RD, Welkie RL, Quaye N, Hankins JS, Kassim AA, Thompson AA, Treadwell M, Lin CJ, Cronin RM. : Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease. Blood Adv. January 2024.

Ntoulia A, Darge K, Thompson AA, Back SJ. : Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait. J Ultrasound Med January 2024.